Matches 1 - 50 out of 111 1 2 3 >


Match Document Document Title
US20120171243 METHOD OF PREPARING LIVE VIRAL VACCINES BY GENETIC ENGINEERING OF VIRAL GENOME  
Disclosed is an attenuation method of an influenza virus, that is, a reassortant virus and a preparation method thereof. The disclosed reassortant virus has, in a ratio of 6:2, genes encoding a...
US20130129781 METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY  
Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local...
US20110162982 Methods for producing vaccine adjuvants  
An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to...
US20140341974 Liposomal Vaccine Adjuvants and Methods of Making and Using Same  
A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: dipalmitoyl phosphatidicholine (DPPC), dipalmitoyl phosphatidylglycerol (DPPG), dioleoyl...
US20140030291 INFLUENZA VIRUS REASSORTMENT  
New influenza donor strains for the production of reassortant influenza A viruses are provided.
US20110212128 Universal virus-like particle (VLP) influenza vaccines  
Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these...
US20130129782 DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES  
Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero,...
US20130209509 H3 EQUINE INFLUENZA A VIRUS  
The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
US20130216573 INFLUENZA VIRUS REASSORTMENT  
Methods for producing reassortant viruses are provided wherein the transcription and/or translation of the hemagglutinin and/or neuraminidase genes are suppressed.
US20150056235 MATERIALS AND METHODS FOR RESPIRATORY DISEASE CONTROL IN CANINES  
The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and...
US20140134208 MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS  
Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid...
US20120288521 MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS  
Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid...
US20140220075 MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS  
Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid...
US20120020997 MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS  
Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid...
US20140328875 INFLUENZA VIRUS VACCINES AND USES THEREOF  
Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.
US20130224144 SEQUENTIAL ADMINISTRATION OF A REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION PROTOCOLS  
Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to...
US20100330118 INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS  
Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.
US20140023680 INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS  
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
US20130243816 INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS  
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
US20130156810 INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS  
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
US20120301503 INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS  
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
US20120034265 INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS  
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
US20120034264 INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS  
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
US20120009215 INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS  
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
US20110212117 INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS  
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
US20110182936 INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS  
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
US20110070263 INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS  
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
US20110002960 INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS  
Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
US20090220541 EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR ADJUVANTING SPLIT INFLUENZA VACCINES  
A split influenza virus vaccine is adjuvanted with an oil-in-water emulsion that contains free surfactant in its aqueous phase. The free surfactant can continue to exert a “splitting effect” on...
US20130224244 VACCINE COMPOSITION FOR VACCINATING DOGS AGAINST CANINE INFECTIOUS RESPIRATORY DISEASE (CIRD)  
A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an...
US20130189303 RECOMBINANT SWINE INFLUENZA VIRUS AND USES THEREOF  
Recombinant, chimeric porcine influenza viruses are disclosed that include hemagglutinin segments from more than one influenza virus subtype. Also described are methods of producing the...
US20120258135 IMMUNOGENIC ANTI-INFLAMMATORY COMPOSITIONS  
The invention provides methods of formulating an anti-inflammatory composition for treating inflammatory conditions in a specific organ or tissue. The method involves selecting at least one...
US20110200635 COMBINED INFLUENZA VACCINES FOR SEASONAL AND PANDEMIC PROTECTION  
Current approaches to influenza vaccination focus either on seasonal strains or pandemic strains. Current seasonal vaccines typically include antigens from two influenza A strains (H1N1 and H3N2)...
US20150153330 sAPP-alpha as a Biomarker for Prediction of Inflammatory and Autoimmune-Related Disorders  
The subject invention pertains to the use of amyloid precursor protein-alpha (sAPP-α) as a biomarker for prediction of a subject's risk of developing inflammatory and/or autoimmune-related...
US20080003239 Yeast-based Vaccine for Inducing an Immune Response  
The invention provided herein relates to vaccines that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral...
US20140341948 ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS  
The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated...
US20120258134 ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS  
The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated...
US20150165020 MICROMOLDED OR 3-D PRINTED PULSATILE RELEASE VACCINE FORMULATIONS  
Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been...
US20110189230 VACCINATION WITH MULTIPLE CLADES OF H5 INFLUENZA A VIRUS  
H5N1 influenza viruses isolated from animals and humans since 2003 separate into distinct clades based on hemagglutinin amino acid sequences. According to the invention, multiple clades are used...
US20100136050 Extracellular Matrix Materials as Vaccine Adjuvants for Diseases Associated with Infectious Pathogens or Toxins  
Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases...
US20120328653 MODIFIED IMMUNIZATION VECTORS  
The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
US20090214537 Serum Resistance Factors of Gram Positive Bacteria  
A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.
US20090098143 VACCINE PRODUCTION FOR PATHOGENIC BIRD VIRAL DISEASES  
The present invention is an improved method for the production of vaccines to transmittable viral pathogens where the virus is pathogenic to the chicken embryos. Bird embryos are selected for...
US20140370032 Multi-strain-reactive Antibodies for Therapy and Diagnosis of Influenza  
The invention relates to a method for isolating a polypeptide reactive to influenza A hemagglutinin, comprising the steps of preparing a library of nucleic acid sequences, wherein each member of...
US20130017216 Modified Influenza Virus For Monitoring And Improving Vaccine Efficiency  
The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as...
US20110104202 Modified Influenza Virus For Monitoring And Improving Vaccine Efficiency  
The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as...
US20090304739 INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS  
Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgG1). This response can be shifted towards a TH1 response...
US20090311288 IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS  
The invention proyides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective...
US20100068223 Storage of Influenza Vaccines Without Refrigeration  
Antigens from individual influenza virus strains are not refrigerated before being combined to make multivalent influenza virus vaccines. Moreover, influenza vaccines are not refrigerated between...
US20070253978 Copy choice recombination and uses thereof  
The instant invention provides methods for determining, predicting and characterizing the genetic variability of a range of organisms, including, e.g., viruses, microbes, cells and multicellular...

Matches 1 - 50 out of 111 1 2 3 >